Finally, given that combination therapy caused decreased cyclin B1 expression in AI-resistant cells, this may represent a unique opportunity to expand the repertoire of cell cycle inhibitors that can be purposed for endocrine resistant HER2+ breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.